Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI)
- Target
- FabI
- Molecular classification
- Enzyme, Reductase
01
Overview
Bacterial enoyl-acyl carrier protein reductase (FabI) is a key enzyme in the type II fatty acid synthesis (FAS-II) pathway, catalyzing the NAD(P)H-dependent reduction of trans-2-enoyl-acyl carrier protein to acyl-ACP. This is the final and rate-determining step in each elongation cycle of fatty acid biosynthesis, making it essential for bacterial growth. FabI is a validated antibacterial target due to its essentiality and structural divergence from human enzymes. Inhibitors targeting FabI are under investigation for treating infections caused by multidrug-resistant bacteria.
- Other names
- ENREnoyl-ACP reductaseInhA (Mycobacterium tuberculosis homolog)
02
Mechanism of action
Inhibition of bacterial fatty acid synthesis by blocking FabI enzyme activity
03
Biological functions
Fatty acid biosynthesisMembrane lipid synthesisReduction of trans-2-enoyl-acyl carrier protein
04
Disease associations
InfectionBacterial infectionsTuberculosisMalaria
05
Safety considerations
Potential for resistance development via point mutations in fabI geneNeed for narrow-spectrum inhibitors to minimize disruption of the microbiome
06
Interacting drugs
AFN-1252
1 more in the full profile.
Beyond the preview
Go deeper on Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI).